Rice's new models over the years are always the most popular when they first come out, but they are not in stock and need to be grabbed.

This is also the hunger marketing that rice has always been criticized for, playing monkey tricks.

When the new rice machine production capacity is increased, it will no longer be as good as the new off-the-shelf machines from competitors, so it can only be sold at a reduced price.

The price reduction also caused Mi Fan to feel that he was losing money when he bought a new phone for the first time. I bought it half a month ago and lost 300 yuan. After a month, I lost 500 yuan.

It’s better to do it next time.

Compared with the previous new models of rice, this time rice mix 4 is more popular and more difficult to get the goods. After being put out at 9 o'clock in the morning, it is gone in less than five seconds.

Lei Jun’s Weibo posts every day are:

"Mr. Lei, hurry up and get your new machine."

“Can the output increase?”

"Can you please stop being a monkey this time? I am a big fan of Xiaomi Mi 6 and really want to buy it this time."

"Mr. Lei, why don't we go to the factory and tighten the screws ourselves?"

"It's not shameful to go out and tighten the screws personally, but it's shameful to play tricks on fans every day."

The unexpected performance of Mimix4, the first brain-computer connected mobile phone, has made Kechuang Biotech’s listing on the Science and Technology Innovation Board even more anticipated by investors.

Kechuang Biotech's quarterly report in the first quarter maintained high growth. The total operating income in a single quarter exceeded that of the whole of 2020, reaching 2.271 billion yuan. The main source of income was the production and sales of endorphins and patent licensing.

The non-net profit in the first quarter was as high as 1.0745 billion, and the net profit rate was 47.3%, close to 50%.

This is because the profits from brain-computer connection patent licensing have not yet been released.

At this time, Kechuang Biotechnology has completed the inquiry and rectification stage of the Shenhai Stock Exchange and has entered the issuance registration process with the China Securities Regulatory Commission.

In this step, the China Securities Regulatory Commission needs to make a decision on whether to agree or disagree with the registration application of Kechuang Biotechnology within 20 working days.

Based on the qualifications and profitability of Kechuang Biotechnology, the China Securities Regulatory Commission has no reason to reject it, especially since it is a high-tech enterprise that is completely native to China.

The Chinese have an absolute controlling stake in it, and their nationality has not been changed for tax avoidance even on the eve of the listing.

The outside world unanimously believes that the China Securities Regulatory Commission will pass the listing approval of Kechuang Biotech as quickly as possible.

On forums such as Oriental Fortune's Stock Bar, Flush Stock Bar, and Snowball, the discussion on science and innovation biology is extremely hot.

"The valuation of 407.293 billion RMB is not high at all. Kechuang Biotech's profit in the first quarter was 1.0745 billion RMB. If the value of endorphins is calculated alone, this valuation is definitely on the high side.

But everyone should consider that Kechuang Biotech is the only player in the field of brain-computer connection. Currently, there is no brain-computer connection company in China that can see Kechuang Biotech’s car taillights.

This year, Kechuang Biotech has signed patent licensing contracts with domestic and foreign first-tier mobile phone brands such as Rice, OV, Huawei, Samsung, and Apple. The patent licensing fees here are calculated based on the number of mobile phones connected to the brain-computer.

According to IDC, the high-end mobile phone market capacity in China in the first half of 2020 was 23.5 million units. I calculate it to be 47 million units for the whole year. It is expected that the high-end market in 2021 will remain unchanged from 2020, which means it will be 47 million units.

Among them, the proportion of brain-computer connected to mobile phones should be 30% according to the lower limit. This is 14.1 million units. The patent licensing fee for a single brain-computer connected to mobile phone is 200 yuan.

Just for the licensing of brain-computer connection patent technology, I calculate it according to the lower limit. The annual profit contributed by this part in 2021 will also be 2.82 billion yuan.

Moreover, 30% of the brain-computer connection to mobile phones is the worst case scenario, considering that the production capacity cannot be increased.

What's more important is that the profit from brain-computer connection is basically net profit. Kechuang Biotechnology adopts the same strategy as Qualcomm in the brain-computer connection. I only do technology licensing and technology research and development.

Kechuang Biotech’s full-year profit in 2021 is expected to be at least 7 billion yuan.

A company holds patents on endorphins and brain-computer connection, and these two subdivided fields of scientific and technological innovation have formed an absolute field.

Is the valuation of 407.293 billion really expensive?

In my opinion, the listing of Kechuang Biotech at this valuation is giving money to everyone. You have not seen that a large number of companies on the Science and Technology Innovation Board are still losing money, and a large number of biopharmaceutical companies on the GEM and the main board enjoy a price-to-earnings ratio of more than 100.

The price-to-earnings ratio of Kechuang Biotechnology is less than 100, and it is a high-growth technology company.

This valuation is really not high at all.

Judging from future profit forecasts, with the release of brain-computer connection chip production capacity, Kechuang Biotech's profits from brain-computer connection patents can still maintain a high growth trend.

The second phase of the endorphin production base has also begun construction, and the profits from this part will be gradually released in the future.

Endorphins not only have analgesic effects, but also have an important role in reducing the addiction to drugs and even dupin.

It has a substitute for analgesia, but there is no substitute for reducing drug addiction. It can be said that endorphins are to Kechuang Biotech what growth hormone is to Changchun Hi-tech, and Pien Tze Huang is to Pien Tze Huang.

But Kechuang Biotechnology does not walk on one leg like those two companies. It also has a brain-computer connection.

The current brain-computer connection is only a very superficial application in this field. In the future, the development of brain-computer connection patents in English, Arabic and other languages ​​will be able to maintain high profit growth for many years.

The second is the application of brain-computer connection in other aspects. I don’t know much about the technology, but judging from the rapid development of science and technology, I believe that science and technology in the future are worth looking forward to.

The only thing that makes me feel unsatisfied is the listing price of Kechuang Biotechnology, with a total share capital of 400 million shares and an issue price of 1,018.23 yuan.

This price is just the listing price, and it will definitely be shot up instantly when it is officially listed. The price per lot is too high, which is very detrimental to retail investors.

Personally, I feel that after the listing of Kechuang Biotech, it will become the exclusive property of institutions like Moutai.

The price of one lot for retail investors is more than 100,000 yuan, and it may be more than 200,000 yuan in the future. It is difficult for this price to withstand fluctuations.

But no matter what the listing price of Kechuang Biotech is, I will buy it and keep it to grow with this great company!"

In places like stock bars, veteran stock investors usually have a calculator in their hands and can quickly calculate the company's profits and future profits.

Anyone who can hang out in A-shares for many years without losing money mostly has some unique skills.

“I have always agreed with the saying that Science and Technology Biotech is to the Science and Technology Innovation Board just like CATL is to the GEM.

Since its establishment, the Science and Technology Innovation Board has not had an overall leader like the main board and the Science and Technology Innovation Board. When Kechuang Biotech completed its B-round investment, I saw it in the news and realized that Kechuang Biotech was the leader of the Science and Technology Innovation Board.

.

How can the giant dragon of the Science and Technology Innovation Board fly if the leader has not come?
Chapter completed!